CRESTONE: Initial Efficacy and Safety of Seribantumab in Solid Tumors Harboring NRG1 Fusions

June 7, 2022June 16, 2022

by Elevation Oncology

Diagnostics Genomic Testing Gene Fusions Data Research NRG1 fusion Partnership Clinical

Presented at 2022 ASCO Annual Meeting

Presented by Daniel R. Carrizosa, MD

Save this Presentation

Download PDF

Other Related Resources

October 16, 2020February 22, 2021

Posters & Oral Presentations

CRESTONE – Clinical Study of REsponse to Seribantumab in TumOrs with NEuregulin-1 (NRG1) Fusions – A Phase 2 Study of the anti-HER3 mAb for Advanced or Metastatic Solid Tumors (NCT04383210) Read More

September 29, 2020February 22, 2021

Posters & Oral Presentations

CRESTONE – Clinical Study of REsponse to Seribantumab in TumOrs with NEuregulin-1 (NRG1) Fusions – A Phase 2 Study of the anti-HER3 mAb for Advanced or Metastatic Solid Tumors (NCT04383210) Read More

October 26, 2020March 1, 2021

Posters & Oral Presentations

The anti-HER3 monoclonal antibody seribantumab effectively inhibits growth of patient-derived and isogenic cell line and xenograft models with NRG1 rearrangements Read More

January 15, 2021April 7, 2021

Posters & Oral Presentations

CRESTONE – Clinical Study of REsponse to Seribantumab in TumOrs with NEuregulin-1 (NRG1) Fusions – A Phase 2 Study of the anti-HER3 mAb for Advanced or Metastatic Solid Tumors (NCT04383210) Read More

March 29, 2021April 8, 2021

Posters & Oral Presentations

CRESTONE – Clinical Study of REsponse to Seribantumab in TumOrs with NEuregulin-1 (NRG1) Fusions Read More

April 10, 2021April 7, 2021

Posters & Oral Presentations

Preclinical activity of seribantumab in gastrointestinal cancers with NRG1 fusions Read More